Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Review Article (Mini-Review)

Current Advances in Novel SARS-CoV-2 Disease (COVID-19) Treatment and Intervention Strategies

Author(s): Mohammad Khalid Parvez* and Kartika Padhan

Volume 2 , Issue 3 , 2021

Published on: 16 November, 2020

Page: [353 - 358] Pages: 6

DOI: 10.2174/2666796701999201116125249

Abstract

Background: During the eleven months of the novel SARS-CoV-2 disease (COVID-19) outbreak in China and its global spread, there is a remarkable understanding of its epidemiology, pathobiology, and clinical management strategies. While countering a heavy toll on health and the economy, world’s regional authorities are enforcing safety guidelines and providing patient care. Currently, there is no globally approved treatment or intervention for COVID-19.

Methods: A structured online literature search for peer-reviewed articles was conducted on PubMed, Europe PMC, Google, WHO, CDC, FDA, and ClinicalTrials portals, using phrases such as COVID-19 treatment and intervention, COVID-19 drugs and COVID-19 vaccines.

Results: Analysis of the retrieved data showed that as a part of ‘Solidarity Clinical Trials’, hundreds of treatment and intervention strategies, including antiviral drugs, cytokine antagonists, convalescent plasma therapy, and vaccine candidates, have been registered worldwide. While remdesivir, the anti- Ebola virus drug, has been approved as an ‘emergency use’ drug in the USA, favipiravir, the anti-flu drug, has been recently approved in Russia. Tocilizumab and sarilumab, the cytokine (IL-6) antagonists, have entered Phase-II/III clinical trials in hospitalized COVID-19 patients. Among the leading vaccine candidates, Phase-III clinical trial results of Moderna, Pfizer and Oxford vaccines seem to be game changers for COVID19.

Conclusion: The world health authorities have strongly and quickly responded to the COVID-19 pandemic. Nonetheless, world bodies must unite in combating this health crisis by developing cost-effective drugs and vaccines and making them accessible to resource-poor countries.

Keywords: SARS-CoV-2, COVID-19, antiviral, chloroquine, remdesivir, vaccine.

Graphical Abstract
[1]
World Health Organization. Coronavirus disease (COVID-19) outbreak situation. Available from:. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
[2]
Parvez MK, Jagirdar RM, Purty RS. Venkata SKS, Agrawal V, Kumar J, Tiwari N. COVID-19 pandemic, understanding the emergence, pathogenesis and containment. World Acad Sci J 2020; 2: 18.
[http://dx.doi.org/10.3892/wasj.2020.59]]
[3]
Gorbalenya AE, Baker SC, Baric RS, et al. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020; 5(4): 536-44.
[http://dx.doi.org/10.1038/s41564-020-0695-z] [PMID: 32123347]
[4]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[5]
Thorlund K, Dron L, Park J, Hsu G, Forrest JI, Mills EJ. A real-time dashboard of clinical trials for COVID-19. Lancet Digit Health 2020; 2(6): e286-7.
[http://dx.doi.org/10.1016/S2589-7500(20)30086-8] [PMID: 32363333]
[6]
Chan JF, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020; 9(1): 221-36.
[http://dx.doi.org/10.1080/22221751.2020.1719902] [PMID: 31987001]
[7]
Cárdenas-Conejo Y, Liñan-Rico A, García-Rodríguez DA, Centeno-Leija S, Serrano-Posada H. An exclusive 42 amino acid signature in pp1ab protein provides insights into the evolutive history of the 2019 novel human-pathogenic coronavirus (SARS-CoV-2). J Med Virol 2020; 92(6): 688-92.
[http://dx.doi.org/10.1002/jmv.25758] [PMID: 32167166]
[8]
Kumar S, Maurya VK, Prasad AK, Bhatt MLB, Saxena SK. Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV). Virusdisease 2020; 31(1): 13-21.
[http://dx.doi.org/10.1007/s13337-020-00571-5] [PMID: 32206694]
[9]
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020; 181(2): 281-92.
[http://dx.doi.org/10.1016/j.cell.2020.02.058]]
[10]
Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J 2019; 16(1): 69.
[http://dx.doi.org/10.1186/s12985-019-1182-0] [PMID: 31133031]
[11]
Leung DT, Tam FC, Ma CH, et al. Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid. J Infect Dis 2004; 190(2): 379-86.
[http://dx.doi.org/10.1086/422040] [PMID: 15216476]
[12]
Wong HYF, Lam HYS, Fong AH, et al. Frequency and distribution of chest radiographic findings in COVID-19 positive patients. Radiology 2019; 296: E72-8.
[http://dx.doi.org/10.1148/radiol.2020201160] [PMID: 32216717]
[13]
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061-9.
[http://dx.doi.org/10.1001/jama.2020.1585] [PMID: 32031570]
[14]
Gu J, Han B, Wang J. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology 2020; 158(6): 1518-9.
[http://dx.doi.org/10.1053/j.gastro.2020.02.054] [PMID: 32142785]
[15]
Parvez MK. Gastrointestinal and hepatobiliary manifestations of coronavirus disease-19, potential implications for healthcare resource-deficient countries. Gastroenterol Hepatol Lett 2020; 2: 7-11.
[http://dx.doi.org/10.18063/ghl.v2i1.250]]
[16]
Parvez MK. COVID-19 and coronaviral hepatitis, evidence of collateral damage. Future Virol 2020; 6: 325-9.
[http://dx.doi.org/10.2217/fvl-2020-0065]
[17]
Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun 2020; 526(1): 135-40.
[http://dx.doi.org/10.1016/j.bbrc.2020.03.044] [PMID: 32199615]
[18]
Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020; 109(5): 531-8.
[http://dx.doi.org/10.1007/s00392-020-01626-9] [PMID: 32161990]
[19]
Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med 2020; 38(7): 1504-7.
[http://dx.doi.org/10.1016/j.ajem.2020.04.048] [PMID: 32317203]
[20]
Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol 2020; 92(4): 418-23.
[http://dx.doi.org/10.1002/jmv.25681] [PMID: 31967327]
[21]
Totura AL, Baric RS. SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Curr Opin Virol 2012; 2(3): 264-75.
[http://dx.doi.org/10.1016/j.coviro.2012.04.004] [PMID: 22572391]
[22]
Yang Y, Shen C. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol 2020; 146(1): 119-127.e4.
[http://dx.doi.org/10.1016/j.jaci.2020.04.027]]
[23]
Lau SKP, Lau CCY, Chan KH, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol 2013; 94(12): 2679-90.
[http://dx.doi.org/10.1099/vir.0.055533-0] [PMID: 24077366]
[24]
Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA 2020; 117(20): 10970-5.
[http://dx.doi.org/10.1073/pnas.2005615117] [PMID: 32350134]
[25]
Wen W, Su W, Tang H, et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discov 2020; 6: 31.
[http://dx.doi.org/10.1038/s41421-020-0168-9] [PMID: 32377375]
[26]
Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther 2020; 5(1): 33.
[http://dx.doi.org/10.1038/s41392-020-0148-4] [PMID: 32296069]
[27]
Clinicaltrials.gov. Clinicaltrials database. Available from:. https://clinicaltrials.gov/ct2/
[28]
Borba MGS. Val FdA, Sampaio VS, et al.Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). MedRxiv 2020; 2020: 1.
[http://dx.doi.org/10.1101/2020.04.07.20056424]
[29]
Chorin E, Dai M, Shulman E, et al. The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin. MedRxiv 2004; 2004: 1.
[http://dx.doi.org/10.1101/2020.04.02.20047050]]
[30]
Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 2020; 382(25): 2411-8.
[http://dx.doi.org/10.1056/NEJMoa2012410] [PMID: 32379955]
[31]
Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; 382(24): 2327-36.
[http://dx.doi.org/10.1056/NEJMoa2007016] [PMID: 32275812]
[32]
Horby P, Lim WS, Emberson JR, et al. Recovery Collaborative Group.. Dexamethasone in hospitalized patients with Covid-19- Preliminary report. N Engl J Med 2020; 2020: 1.
[http://dx.doi.org/10.1056/NEJMoa2021436]] [PMID: 32678530]
[33]
Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood 2020; 135(21): 1912-5.
[http://dx.doi.org/10.1182/blood.2020006288] [PMID: 32302379]
[34]
Cavalli G, Luca GD, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2020; 2020: 1.
[http://dx.doi.org/10.1016/S2665-9913(20)30127-2]]
[35]
Thanh T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020; 19(5): 305-6.
[http://dx.doi.org/10.1038/d41573-020-00073-5] [PMID: 32273591]
[36]
Jackson LA, Anderson EJ, Rouphael NG, et al. mRNA-1273 Study Group. An mRNA vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med 2020; 2020: 1.
[http://dx.doi.org/10.1056/NEJMoa2022483] [PMID: 32663912]
[37]
Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: Interim report. MedRxiv 2020; 2020: 1.
[http://dx.doi.org/10.1101/2020.06.30.20142570]]
[38]
Folegatti PM, Ewer KJ, Aley PK, et al. Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396(10249): 467-78.
[http://dx.doi.org/10.1016/S0140-6736(20)31604-4] [PMID: 32702298]
[39]
Li XL, Ezelle HJ, Hsi TY, Hassel BA. A central role for RNA in the induction and biological activities of type 1 interferons. Wiley Interdiscip Rev RNA 2011; 2(1): 58-78.
[http://dx.doi.org/10.1002/wrna.32] [PMID: 21956969]
[40]
Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020; 395(10240): 1845-54.
[http://dx.doi.org/10.1016/S0140-6736(20)31208-3] [PMID: 32450106]
[41]
Cohen JUS. ‘Warp Speed’ vaccine effort comes out of the shadows. Science 2020; 368: 992-693..
[http://dx.doi.org/10.1126/science.368.6492.692]

© 2022 Bentham Science Publishers | Privacy Policy